Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: ZNF106

Gene summary for ZNF106

Gene summary.

Gene information	Species	Human
	Gene symbol	ZNF106
	Gene ID	64397
	Gene name	zinc finger protein 106
	Gene Alias	SH3BP3
	Cytomap	15q15.1
	Gene Type	protein-coding
	GO ID	GO:0007154
	UniProtAcc	A0A0C4DGM5

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
64397	ZNF106	CRC-3-11773	Human	Colorectum	CRC	1.85e-02	-1.01e-01	0.2564
64397	ZNF106	LZE2T	Human	Esophagus	ESCC	4.26e-04	1.06e+00	0.082
64397	ZNF106	LZE4T	Human	Esophagus	ESCC	2.81e-12	4.89e-01	0.0811
64397	ZNF106	LZE5T	Human	Esophagus	ESCC	7.00e-04	3.99e-01	0.0514
64397	ZNF106	LZE7T	Human	Esophagus	ESCC	1.90e-05	4.83e-01	0.0667
64397	ZNF106	LZE8T	Human	Esophagus	ESCC	4.35e-06	2.80e-01	0.067
64397	ZNF106	LZE20T	Human	Esophagus	ESCC	1.24e-03	2.33e-02	0.0662
64397	ZNF106	LZE24T	Human	Esophagus	ESCC	8.91e-08	2.70e-01	0.0596
64397	ZNF106	LZE21T	Human	Esophagus	ESCC	1.86e-04	2.03e-01	0.0655
64397	ZNF106	LZE6T	Human	Esophagus	ESCC	2.16e-02	1.33e-01	0.0845
64397	ZNF106	P1T-E	Human	Esophagus	ESCC	4.69e-09	5.87e-01	0.0875
64397	ZNF106	P2T-E	Human	Esophagus	ESCC	7.00e-21	5.37e-01	0.1177
64397	ZNF106	P4T-E	Human	Esophagus	ESCC	2.00e-20	4.61e-01	0.1323
64397	ZNF106	P5T-E	Human	Esophagus	ESCC	1.40e-11	1.65e-01	0.1327
64397	ZNF106	P8T-E	Human	Esophagus	ESCC	1.42e-29	5.04e-01	0.0889
64397	ZNF106	P9T-E	Human	Esophagus	ESCC	5.46e-18	3.94e-01	0.1131
64397	ZNF106	P10T-E	Human	Esophagus	ESCC	8.74e-39	6.99e-01	0.116
64397	ZNF106	P11T-E	Human	Esophagus	ESCC	2.88e-10	4.67e-01	0.1426
64397	ZNF106	P12T-E	Human	Esophagus	ESCC	8.99e-33	5.20e-01	0.1122
64397	ZNF106	P15T-E	Human	Esophagus	ESCC	6.09e-22	5.03e-01	0.1149

Page: 1 2 3 4 5 6 7 8 9

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:0032868	Colorectum	AD	response to insulin	91/3918	264/18723	2.02e-07	8.48e-06	91
GO:1901653	Colorectum	AD	cellular response to peptide	114/3918	359/18723	8.32e-07	2.88e-05	114
GO:0032869	Colorectum	AD	cellular response to insulin stimulus	72/3918	203/18723	1.10e-06	3.68e-05	72
GO:0071375	Colorectum	AD	cellular response to peptide hormone stimulus	95/3918	290/18723	1.50e-06	4.66e-05	95
GO:0043434	Colorectum	AD	response to peptide hormone	126/3918	414/18723	2.70e-06	7.86e-05	126
GO:00434343	Colorectum	FAP	response to peptide hormone	100/2622	414/18723	1.74e-08	1.84e-06	100
GO:19016533	Colorectum	FAP	cellular response to peptide	89/2622	359/18723	2.93e-08	2.64e-06	89
GO:00713753	Colorectum	FAP	cellular response to peptide hormone stimulus	75/2622	290/18723	5.60e-08	4.29e-06	75
GO:00328683	Colorectum	FAP	response to insulin	68/2622	264/18723	2.71e-07	1.55e-05	68
GO:00328693	Colorectum	FAP	cellular response to insulin stimulus	54/2622	203/18723	1.54e-06	6.59e-05	54
GO:0008286	Colorectum	FAP	insulin receptor signaling pathway	28/2622	116/18723	2.37e-03	1.89e-02	28
GO:00434344	Colorectum	CRC	response to peptide hormone	76/2078	414/18723	6.67e-06	2.56e-04	76
GO:00328684	Colorectum	CRC	response to insulin	53/2078	264/18723	1.30e-05	4.17e-04	53
GO:00328694	Colorectum	CRC	cellular response to insulin stimulus	42/2078	203/18723	4.79e-05	1.12e-03	42
GO:00713754	Colorectum	CRC	cellular response to peptide hormone stimulus	55/2078	290/18723	4.82e-05	1.12e-03	55
GO:19016534	Colorectum	CRC	cellular response to peptide	64/2078	359/18723	8.54e-05	1.75e-03	64
GO:00082861	Colorectum	CRC	insulin receptor signaling pathway	23/2078	116/18723	4.02e-03	3.33e-02	23
GO:190165319	Esophagus	ESCC	cellular response to peptide	208/8552	359/18723	1.68e-06	2.01e-05	208
GO:0043434111	Esophagus	ESCC	response to peptide hormone	234/8552	414/18723	4.93e-06	5.21e-05	234
GO:003286918	Esophagus	ESCC	cellular response to insulin stimulus	124/8552	203/18723	6.63e-06	6.75e-05	124

Page: 1 2 3 4

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

ZNF106

SNV

Missense_Mutation

c.4483G>C

p.Glu1495Gln

p.E1495Q

Q9H2Y7

protein_coding

tolerated(0.05)

probably_damaging(0.991)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

ZNF106

SNV

Missense_Mutation

c.281T>C

p.Ile94Thr

p.I94T

Q9H2Y7

protein_coding

tolerated(0.7)

benign(0)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

ZNF106

SNV

Missense_Mutation

novel

c.4655C>A

p.Thr1552Asn

p.T1552N

Q9H2Y7

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

ZNF106

SNV

Missense_Mutation

novel

c.1181C>A

p.Thr394Asn

p.T394N

Q9H2Y7

protein_coding

tolerated_low_confidence(0.12)

benign(0)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

ZNF106

SNV

Missense_Mutation

rs574435008

c.937G>A

p.Asp313Asn

p.D313N

Q9H2Y7

protein_coding

tolerated(0.46)

benign(0.003)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

ZNF106

SNV

Missense_Mutation

c.865N>A

p.Gly289Ser

p.G289S

Q9H2Y7

protein_coding

tolerated(0.24)

benign(0.007)

TCGA-AO-A03R-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

ZNF106

SNV

Missense_Mutation

c.1261N>A

p.Asp421Asn

p.D421N

Q9H2Y7

protein_coding

tolerated(0.2)

benign(0.041)

TCGA-D8-A1J8-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

nolvadex

ZNF106

SNV

Missense_Mutation

rs147629444

c.512N>T

p.Ser171Phe

p.S171F

Q9H2Y7

protein_coding

tolerated(0.05)

possibly_damaging(0.707)

TCGA-D8-A1JA-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

adriamycin

ZNF106

SNV

Missense_Mutation

c.1122N>C

p.Met374Ile

p.M374I

Q9H2Y7

protein_coding

tolerated(0.46)

benign(0)

TCGA-D8-A1JN-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Hormone Therapy

anastrozolum

ZNF106

SNV

Missense_Mutation

c.2549C>G

p.Ser850Trp

p.S850W

Q9H2Y7

protein_coding

deleterious(0)

probably_damaging(0.925)

TCGA-E2-A14X-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

doxorubicin

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1